

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-72. (canceled)

73. (Currently Amended) An amphiphilic drug-oligomer conjugate comprising a therapeutic compound comprising an enkephalin compound conjugated to an oligomer, wherein the oligomer comprises a lipophilic moiety coupled to a hydrophilic moiety, and wherein the oligomer has the formula:



wherein

m = 1 to 6;

n = 0 or 1;

x = 0, 3 or 6;

y = 1, 2, 3 or 6;

z = 2, 3, 7 or 8;

A = single bond, CO or CONHCH₂CH₂; and

E = OH or OCH₂COOH.

74. (Canceled).

75. (Previously Presented) The amphiphilic drug-oligomer conjugate of claim 73, wherein the amphiphilic drug-oligomer conjugate exhibits the biological activity of the therapeutic compound without cleavage of the therapeutic compound from the oligomer.

76. (Previously Presented) The amphiphilic drug-oligomer conjugate of claim 73, wherein the amphiphilic drug-oligomer conjugate does not exhibit the biological activity of the therapeutic compound without cleavage of the therapeutic compound from the oligomer.

77. (Previously Presented) The amphiphilic drug-oligomer conjugate of claim 73, wherein the

lipophilic moiety is coupled to the hydrophilic moiety by a hydrolyzable bond.

78. (Previously Presented) The amphiphilic drug-oligomer conjugate of claim 73, wherein the lipophilic moiety is coupled to the hydrophilic moiety by a non-hydrolyzable bond.

79. (Previously Presented) The amphiphilic drug-oligomer conjugate of claim 73, wherein the lipophilic moiety is coupled to the hydrophilic moiety by a bond selected from the group consisting of: amide bond, carbamate bond, carbonate bond and ester bond.

80. (Previously Presented) The amphiphilic drug-oligomer conjugate of claim 73, wherein the oligomer is coupled to the therapeutic compound by a bond selected from the group consisting of amide bond, carbamate bond, carbonate bond and ester bond.

81. (Currently Amended) The amphiphilic drug-oligomer conjugate of claim 73, wherein the ~~therapeutic compound is a peptide having~~ enkephalin compound comprises an added N-terminal residue selected from the group consisting of proline and alanine.

82. (Canceled).

83. (Currently Amended) The amphiphilic drug-oligomer conjugate of claim 73, wherein the ~~therapeutic compound is an~~ enkephalin compound is met-enkephalin-lys (SEQ ID NO:1) or an analog thereof.

84. (Currently Amended). The amphiphilic drug-oligomer conjugate of claim 73, wherein the ~~therapeutic~~ enkephalin compound is met⁵-enkephalin (SEQ ID NO:48) or an analog thereof.

85. (Previously Presented) The amphiphilic drug-oligomer conjugate of claim 73, wherein the therapeutic compound is met-enkephalin-lys (SEQ ID NO:1) and the oligomer has the formula:



wherein $m = 1$, $n = 0$, $\text{A} = \text{CONHCH}_2\text{CH}_2$, $\text{E} = \text{OH}$, $x = 0$, $y = 6$, and $z = 2$.

86. (Previously Presented) The amphiphilic drug-oligomer conjugate of claim 73, wherein the therapeutic compound is met-enkephalin-lys (SEQ ID NO:1) and the oligomer has the formula:



wherein $m = 1$, $n = 0$, $\text{A} = \text{CONHCH}_2\text{CH}_2$, $\text{E} = \text{OH}$, $x = 3$, $y = 2$, and $z = 7$.